NCT06311045

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Basis of Sex-specific Therapeutic Responses to Obstructive Sleep Apnea (OSA): a Trial of N-acetylcysteine (NAC) in Obstructive Sleep Apnea (OSA)

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 55 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

Conditions

• Obstructive Sleep Apnea

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	N-acetylcysteine (NAC)	Participants will take two NAC 600mg capsules daily for four weeks.
DIETARY_SUPPLEMENT	Placebo	Participants will take two placebo 600mg capsules daily for four weeks.
PROCEDURE	Positive Airway Pressure (PAP) Therapy	All participants will receive PAP therapy per standard of care for OSA.

Timeline

• Start date: 2024-05-07
• Primary completion: 2026-03-01
• Completion: 2026-04-01
• First posted: 2024-03-15
• Last updated: 2026-03-04

Locations

1 site across 1 country: United States